These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 22357510)
1. Isolation of more potent oncolytic paramyxovirus by bioselection. Beier R; Hermiston T; Mumberg D Gene Ther; 2013 Jan; 20(1):102-11. PubMed ID: 22357510 [TBL] [Abstract][Full Text] [Related]
2. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956 [TBL] [Abstract][Full Text] [Related]
3. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Fournier P; Bian H; Szeberényi J; Schirrmacher V Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477 [TBL] [Abstract][Full Text] [Related]
4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179 [TBL] [Abstract][Full Text] [Related]
5. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743 [TBL] [Abstract][Full Text] [Related]
6. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620 [TBL] [Abstract][Full Text] [Related]
7. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533 [TBL] [Abstract][Full Text] [Related]
8. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930 [TBL] [Abstract][Full Text] [Related]
9. Apoptin enhances the oncolytic properties of Newcastle disease virus. Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658 [TBL] [Abstract][Full Text] [Related]
10. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V Int J Oncol; 2005 Feb; 26(2):431-9. PubMed ID: 15645128 [TBL] [Abstract][Full Text] [Related]
11. [Progress in using Newcastle disease virus for tumor therapy: a review]. Wu Y; Hao J; Li D Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105 [TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973 [TBL] [Abstract][Full Text] [Related]
13. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405 [TBL] [Abstract][Full Text] [Related]
14. The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect. Jung BK; An YH; Jang SH; Jang JJ; Kim S; Jeon JH; Kim J; Song JJ; Jang H Virol J; 2024 Jan; 21(1):7. PubMed ID: 38178138 [TBL] [Abstract][Full Text] [Related]
15. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068 [TBL] [Abstract][Full Text] [Related]
17. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Vigil A; Martinez O; Chua MA; García-Sastre A Mol Ther; 2008 Nov; 16(11):1883-90. PubMed ID: 18714310 [TBL] [Abstract][Full Text] [Related]
18. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582 [TBL] [Abstract][Full Text] [Related]
19. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Zeng J; Fournier P; Schirrmacher V Int J Oncol; 2004 Aug; 25(2):293-302. PubMed ID: 15254725 [TBL] [Abstract][Full Text] [Related]
20. Newcastle disease virus as an oncolytic agent. Ravindra PV; Tiwari AK; Sharma B; Chauhan RS Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]